RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
SCI Pharmtech - Stock

SCI Pharmtech EBIT 2024

SCI Pharmtech EBIT

160.3 M TWD

SCI Pharmtech Dividend yield

0.24 %

Ticker

4119.TW

ISIN

TW0004119003

In 2024, SCI Pharmtech's EBIT was 160.3 M TWD, a 34.74% increase from the 118.97 M TWD EBIT recorded in the previous year.

The SCI Pharmtech EBIT history

YEAREBIT (undefined TWD)
20230.16
20220.12
20210.07
20201.05
20190.7
20180.52
20170.23
20160.52
20150.44
20140.3
20130.21
20120.25
20110.19
20100.21
20090.21
20080.2
20070.17
20060.04
20050.05
20040.06

SCI Pharmtech Aktienanalyse

What does SCI Pharmtech do?

SCI Pharmtech Inc is a leading company in the pharmaceutical industry based in Zhejiang, China. The company was founded in 2003 and has since grown continuously. Today, the company employs over 100 employees and has become a key player in the global supply chain of pharmaceutical raw materials and intermediates. SCI Pharmtech Inc's business model is based on the development and production of high-quality pharmaceutical intermediates and active pharmaceutical ingredients, as well as the manufacturing of custom chemicals. The company specializes in the production and distribution process, offering its customers a comprehensive range of products that meet the highest quality and safety standards. SCI Pharmtech Inc is divided into various divisions, each specializing in specific product categories. The main divisions are API (Active Pharmaceutical Ingredients), intermediates, and custom synthesis. The API division produces active pharmaceutical ingredients for the pharmaceutical industry, which serve as the basis for drug manufacturing. The intermediates division offers pharmaceutical intermediates used in the synthesis of active pharmaceutical ingredients. The custom synthesis division provides tailored synthesis processes for customers in need of specific chemicals or intermediates. SCI Pharmtech Inc's product portfolio includes Acetamidomalonate, Carbamazepine, and Codergocrine Mesylate, among others. The company also offers custom synthesis services, involving complex chemical syntheses and innovative technologies. SCI Pharmtech Inc places great emphasis on quality and safety. The company operates according to international standards, including GMP (Good Manufacturing Practice), ISO (International Standards Organization), and CE (Conformité Européenne). SCI Pharmtech Inc's products undergo stringent quality controls to ensure compliance with the strict regulations of global pharmaceutical regulatory authorities. Another important concern of SCI Pharmtech Inc is sustainability. The company has developed a sustainable business strategy aimed at minimizing its environmental impact and conserving resources. This includes implementing efficient production processes, reducing energy consumption and CO2 emissions, as well as promoting environmental awareness among employees and customers. Overall, SCI Pharmtech Inc is a dynamic and innovative company specializing in the production of pharmaceutical intermediates and active pharmaceutical ingredients. The company takes pride in offering high-quality products that meet the highest quality and safety standards. Through its sustainable business strategy and adherence to international standards, SCI Pharmtech Inc has achieved an excellent reputation in the pharmaceutical industry and strengthened its presence in the global market. SCI Pharmtech ist eines der beliebtesten Unternehmen auf Eulerpool.com.

EBIT Details

Analyzing SCI Pharmtech's EBIT

SCI Pharmtech's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.

Year-to-Year Comparison

A yearly comparison of SCI Pharmtech's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.

Impact on Investments

SCI Pharmtech's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.

Interpreting EBIT Fluctuations

Fluctuations in SCI Pharmtech’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.

Frequently Asked Questions about SCI Pharmtech Stock

How much did SCI Pharmtech achieve in EBIT for the current year?

In the current year, SCI Pharmtech has achieved an EBIT of 160.3 M TWD.

What is EBIT?

EBIT stands for Earnings Before Interest and Taxes and refers to the profit before interest and taxes of a company SCI Pharmtech.

How has the EBIT of SCI Pharmtech developed in recent years?

The EBIT of SCI Pharmtech has increased by 34.74% increased compared to the previous year.

What does EBIT mean for investors?

EBIT provides investors with insights into a company's profitability as it reflects the profit before interest expenses and taxes.

Why is EBIT an important indicator for investors?

Since EBIT provides a more direct insight into a company's profit than net income, it is an important indicator for investors to assess the profitability of a company.

Why do EBIT values fluctuate?

EBIT values can fluctuate as they are influenced by various factors, such as revenue, costs, and tax effects.

What role does tax burden play in EBIT?

Tax burdens have a direct impact on a company's EBIT, as they are deducted from the profit.

How is EBIT presented in the balance sheet of the company SCI Pharmtech?

The EBIT of SCI Pharmtech is listed in the income statement.

Can EBIT be used as a single indicator for evaluating a company?

EBIT is an important indicator for evaluating a company, but additional financial ratios should also be considered to get a comprehensive picture.

Why is EBIT not equal to net profit?

The net profit of a company includes taxes and interest, while EBIT represents the profit before interest and taxes.

How much dividend does SCI Pharmtech pay?

Over the past 12 months, SCI Pharmtech paid a dividend of 0.22 TWD . This corresponds to a dividend yield of about 0.24 %. For the coming 12 months, SCI Pharmtech is expected to pay a dividend of 0.22 TWD.

What is the dividend yield of SCI Pharmtech?

The current dividend yield of SCI Pharmtech is 0.24 %.

When does SCI Pharmtech pay dividends?

SCI Pharmtech pays a quarterly dividend. This is distributed in the months of August, August, September, August.

How secure is the dividend of SCI Pharmtech?

SCI Pharmtech paid dividends every year for the past 1 years.

What is the dividend of SCI Pharmtech?

For the upcoming 12 months, dividends amounting to 0.22 TWD are expected. This corresponds to a dividend yield of 0.24 %.

In which sector is SCI Pharmtech located?

SCI Pharmtech is assigned to the 'Health' sector.

Wann musste ich die Aktien von SCI Pharmtech kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of SCI Pharmtech from 9/1/2023 amounting to 0.222 TWD, you needed to have the stock in your portfolio before the ex-date on 7/27/2023.

When did SCI Pharmtech pay the last dividend?

The last dividend was paid out on 9/1/2023.

What was the dividend of SCI Pharmtech in the year 2023?

In the year 2023, SCI Pharmtech distributed 0.417 TWD as dividends.

In which currency does SCI Pharmtech pay out the dividend?

The dividends of SCI Pharmtech are distributed in TWD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von SCI Pharmtech

Our stock analysis for SCI Pharmtech Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of SCI Pharmtech Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.